AntidiabeticsINJECTIONStandard
HUMALOG TEMPO PEN
INSULIN LISPRO RECOMBINANT
Standard Dose
100UNITS/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview HUMALOG TEMPO PEN is listed in Drugs@FDA under application 020563 (BLA).
Review priority: STANDARD Marketing status: Prescription Active ingredient INSULIN LISPRO RECOMBINANT Form and strength INJECTABLE;INJECTION - 100UNITS/ML Sponsor LILLY Submission history Latest submission status date: 2025-05-07 00:00:00.
Structured Monograph
Clinical summary
Approval overview HUMALOG TEMPO PEN is listed in Drugs@FDA under application 020563 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient INSULIN LISPRO RECOMBINANT Form and strength INJECTABLE;INJECTION - 100UNITS/ML Sponsor LILLY Submission history Latest submission status date: 2025-05-07 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.